Aditxt, Inc. Operating Cash Flow
Aditxt, Inc. (ADTX) reported Operating Cash Flow of -$4.58 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-05-20
- Aditxt, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.58M.
- Aditxt, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$9.25M.
- Aditxt, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.34M.
- Aditxt, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$2.38M.
- Aditxt, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$25.69M.
- Aditxt, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$16.76M.
- Aditxt, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$19.20M.
- Aditxt, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$22.39M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | -$4.58M 10-Q · filed 2026-05-20 | -$13.82M derived: sum of 2 quarters · filed 2026-05-20 | -$16.17M derived: sum of 3 quarters · filed 2026-05-20 | -$18.55M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2025-12-31 | -$9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$11.59M derived: sum of 2 quarters · filed 2026-03-31 | -$13.97M derived: sum of 3 quarters · filed 2026-03-31 | -$25.69M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$4.73M derived: sum of 2 quarters · filed 2025-11-18 | -$16.44M 10-Q · filed 2025-11-18 | -$22.59M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2025-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$14.10M 10-Q · filed 2025-08-14 | -$20.25M derived: sum of 3 quarters · filed 2026-05-20 | -$22.61M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2025-03-31 | -$11.71M 10-Q · filed 2026-05-20 | -$17.86M derived: sum of 2 quarters · filed 2026-05-20 | -$20.22M derived: sum of 3 quarters · filed 2026-05-20 | -$22.51M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2024-12-31 | -$6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$8.51M derived: sum of 2 quarters · filed 2026-03-31 | -$10.80M derived: sum of 3 quarters · filed 2026-03-31 | -$16.76M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$4.65M derived: sum of 2 quarters · filed 2025-11-18 | -$10.62M 10-Q · filed 2025-11-18 | -$14.55M derived: sum of 4 quarters · filed 2025-11-18 | ||
| 2024-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$8.25M 10-Q · filed 2025-08-14 | -$12.19M derived: sum of 3 quarters · filed 2025-08-14 | -$20.22M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$5.96M 10-Q · filed 2025-05-15 | -$9.90M derived: sum of 2 quarters · filed 2025-05-15 | -$17.93M derived: sum of 3 quarters · filed 2025-05-15 | -$21.21M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$11.97M derived: sum of 2 quarters · filed 2025-03-31 | -$15.25M derived: sum of 3 quarters · filed 2025-03-31 | -$19.20M 10-K · filed 2025-03-31 | -$18.58M 10-K · filed 2024-04-16 | |
| 2023-09-30 | -$8.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$11.32M derived: sum of 2 quarters · filed 2024-11-18 | -$15.27M 10-Q · filed 2024-11-18 | -$21.99M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2023-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$7.23M 10-Q · filed 2024-08-19 | -$13.95M derived: sum of 3 quarters · filed 2024-08-19 | -$21.77M derived: sum of 4 quarters · filed 2024-08-19 | ||
| 2023-03-31 | -$3.95M 10-Q · filed 2024-05-20 | -$10.67M derived: sum of 2 quarters · filed 2024-05-20 | -$18.49M derived: sum of 3 quarters · filed 2024-05-20 | -$21.14M derived: sum of 4 quarters · filed 2024-05-20 | ||
| 2022-12-31 | -$6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$14.54M derived: sum of 2 quarters · filed 2024-04-16 | -$17.19M derived: sum of 3 quarters · filed 2024-04-16 | -$22.39M 10-K · filed 2024-04-16 | ||
| 2022-09-30 | -$7.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$10.47M derived: sum of 2 quarters · filed 2023-11-14 | -$15.67M 10-Q · filed 2023-11-14 | -$24.36M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$7.85M 10-Q · filed 2023-08-14 | -$16.54M derived: sum of 3 quarters · filed 2023-08-14 | -$21.07M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$5.20M 10-Q · filed 2023-05-15 | -$13.89M derived: sum of 2 quarters · filed 2023-05-15 | -$18.42M derived: sum of 3 quarters · filed 2023-05-15 | -$23.42M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | -$13.22M derived: sum of 2 quarters · filed 2023-04-17 | -$18.22M derived: sum of 3 quarters · filed 2023-04-17 | -$22.28M 10-K · filed 2023-04-17 | ||
| 2021-09-30 | -$4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$9.53M derived: sum of 2 quarters · filed 2022-11-14 | -$13.59M 10-Q · filed 2022-11-14 | -$16.73M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$5.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$9.06M 10-Q · filed 2022-08-15 | -$12.21M derived: sum of 3 quarters · filed 2022-08-15 | -$15.88M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$4.05M 10-Q · filed 2022-05-16 | -$7.20M derived: sum of 2 quarters · filed 2022-05-16 | -$10.87M derived: sum of 3 quarters · filed 2022-05-16 | -$11.02M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$6.82M derived: sum of 2 quarters · filed 2022-03-31 | -$6.97M derived: sum of 3 quarters · filed 2022-03-31 | -$7.22M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$3.82M derived: sum of 2 quarters · filed 2021-11-15 | -$4.07M 10-Q · filed 2021-11-15 | -$4.07M 10-Q · filed 2020-11-13 | -$4.12M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | -$154.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$405.59K 10-Q · filed 2021-08-12 | -$454.54K derived: sum of 3 quarters · filed 2021-08-12 | -$560.74K derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$250.92K 10-Q · filed 2021-05-12 | -$299.86K derived: sum of 2 quarters · filed 2021-05-12 | -$406.06K derived: sum of 3 quarters · filed 2021-05-12 | |||
| 2019-12-31 | -$48.95K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$155.15K derived: sum of 2 quarters · filed 2021-03-25 | -$464.35K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$106.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$415.41K 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | -$309.21K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |